Bijlani Vishal, Yuonayel Domotiere, Katpally Sabitha, Chukwumezie Beatrice Nkem, Adeyeye Moji Christianah
Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA.
AAPS PharmSciTech. 2007 Jul 6;8(3):E52. doi: 10.1208/pt0803052.
The objective of the study was to produce rapidly dissolving formulations of the poorly water-soluble drug repaglinide using an innovative new technology, ultra-rapid freezing (URF), and to investigate the influence of excipient type on repaglinide stability. Repaglinide compositions containing different types and levels of excipients and different drug potencies (50%–86%) were produced by the URF technology. Repaglinide/excipient solutions were frozen on a cryogenic substrate, collected, and lyophilized to form a dry powder. Surfactants, including sodium dodecyl sulfate, and alkalizing agents such as diethanolamine (DEA) and tromethamine (TRIS) were incorporated into the compositions. Forced degradation of repaglinide was conducted under stressed conditions (eg, elevated temperature, exposure to peroxide) to determine the stability of the drug in such environments. The solubility of repaglinide increased as a function of increasing pH; therefore, incorporation of an alkalizing agent into the URF formulations increased the drug's solubility. Drug instability resulted when the drug was exposed to pH values above 9.0. URF formulations containing alkalizing agents showed no degradation or spontaneous recrystallization in the formulation, indicating that increased stability was afforded by processing. URF processing created nanostructured drug/excipient particles with higher dissolution rates than were achieved for unprocessed drug. Alkalizing agents such as TRIS and DEA, present at levels of 25% to 33% wt/wt in the formulations, did not cause degradation of the drug when processed using URF. URF processing, therefore, yielded fast-dissolving formulations that were physically and chemically stable, resistant to alkali degradation or spontaneous recrystallization in the formulation.
本研究的目的是使用一种创新的新技术——超快速冷冻(URF)来制备水溶性差的药物瑞格列奈的快速溶解制剂,并研究辅料类型对瑞格列奈稳定性的影响。通过URF技术制备了含有不同类型和水平的辅料以及不同药物效价(50%–86%)的瑞格列奈组合物。将瑞格列奈/辅料溶液冷冻在低温基质上,收集后冻干形成干粉。组合物中加入了表面活性剂,如十二烷基硫酸钠,以及碱化剂,如二乙醇胺(DEA)和三羟甲基氨基甲烷(TRIS)。在强制条件下(如升高温度、暴露于过氧化物)对瑞格列奈进行强制降解,以确定药物在这种环境中的稳定性。瑞格列奈的溶解度随pH值升高而增加;因此,在URF制剂中加入碱化剂可提高药物的溶解度。当药物暴露于pH值高于9.0时会导致药物不稳定。含有碱化剂的URF制剂在制剂中未显示降解或自发重结晶,表明加工提高了稳定性。URF加工产生了纳米结构的药物/辅料颗粒,其溶解速率高于未加工药物。制剂中含量为25%至33% wt/wt的TRIS和DEA等碱化剂在使用URF加工时不会导致药物降解。因此,URF加工产生了物理和化学稳定、抗碱降解或制剂中自发重结晶的快速溶解制剂。